A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: The onset of drug resistance is a major cause of treatment failure in multiple myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug resistance, their potential activity as drug-sensitizing agents has not yet been investigated in multiple myeloma. Experimental Design: Here we studied the potential utility of miR-221/222 inhibition in sensitizing refractory multiple myeloma cells to melphalan. Results: miR-221/222 expression inversely correlated with melphalan sensitivity of multiple myeloma cells. Inhibition of miR-221/222 overcame melphalan resistance and triggered apoptosis of multiple myeloma cells in vitro, in the presence or absence of human bone marrow (BM) stromal cells. Decreased multiple myeloma cell growth induced by inhibition of miR-221/222 plus melphalan was associated with a marked upregulation of pro-apoptotic BBC3/PUMA protein, a miR-221/222 target, as well as with modulation of drug influx–efflux transporters SLC7A5/LAT1 and the ABC transporter ABCC1/MRP1. Finally, in vivo treatment of SCID/NOD mice bearing human melphalan-refractory multiple myeloma xenografts with systemic locked nucleic acid (LNA) inhibitors of miR-221 (LNA-i-miR-221) plus melphalan overcame drug resistance, evidenced by growth inhibition with significant antitumor effects together with modulation of PUMA and ABCC1 in tumors retrieved from treated mice. Conclusions: Taken together, our findings provide the proof of concept that LNA-i-miR-221 can reverse melphalan resistance in preclinical models of multiple myeloma, providing the framework for clinical trials to overcome drug resistance, and improve patient outcome in multiple myeloma. Clin Cancer Res; 22(5); 1222–33. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · cited 1×
“Presently its therapeutic value is in younger patients who undergo high-dose melphalan prior to autologous stem cell transplantation, as well as in nontransplant candidates or elderly patients as a part of first-line combination regimens (10, 11).”
BackgroundTargeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
Leone, E., Morelli, E., Di Martino, M. T., Amodio, N., Foresta, U., Gullà, A., Rossi, M., Neri, A., Giordano, A., Munshi, N. C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3325 · Cited by 219
Self-citation
Cited by
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
Amodio, N., Raimondi, L., Juli, G., Stamato, M. A., Caracciolo, D., Tagliaferri, P., & Tassone, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0606-4 · Cited by 348
Self-citationAmodio, N., Stamato, M. A., Juli, G., Morelli, E., Fulciniti, M., Manzoni, M., Taiana, E., Agnelli, L., Cantafio, M. E. G., Romeo, E., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0067-3 · Cited by 260
Self-citationMicroRNA: A novel target of curcumin in cancer therapy
Mirzaei, H., Masoudifar, A., Sahebkar, A., Zare, N., Sadri Nahand, J., Rashidi, B., Mehrabian, E., Mohammadi, M., Mirzaei, H. R., & Jaafari, M. R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26055 · Cited by 236
Metadata
- Authors
- Gullà, A., Di Martino, M. T., Gallo Cantafio, M. E., Morelli, E., Amodio, N., Botta, C., Pitari, M. R., Lio, S. G., Britti, D., Stamato, M. A., Hideshima, T., Munshi, N. C., Anderson, K. C., Tagliaferri, P., & Tassone, P.
- Venue
- Clinical Cancer Research
- Published
- 2016-02-29
- Volume
- 22
- Issue
- 5
- Pages
- 1222-1233
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1909496986
- Cited by
- 120
- References
- 3
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0489
- The paper
- Gullà, A., Di Martino, M. T., Gallo Cantafio, M. E., Morelli, E., Amodio, N., Botta, C., Pitari, M. R., Lio, S. G., Britti, D., Stamato, M. A., Hideshima, T., Munshi, N. C., Anderson, K. C., Tagliaferri, P., & Tassone, P. (2016). A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0489
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.